According to the draft papers, Concord Biotech s IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investment Holdings Pte Limited, backed by private equity firm Quadria Capital.
Concord is among the leading manufacturers of fermentation-based biopharmaceutical APIs focused on niche segments, such as immunosuppressant, oncology, anti-fungal and anti-bacterial.
Concord Biotech IPO: Rare Enterprises-backed Concord Biotech has filed draft papers with the capital markets regulator SEBI to mop up funds through an initial public offering (IPO).